Annual report pursuant to Section 13 and 15(d)

Segments (Details)

v2.4.0.6
Segments (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Information regarding our geographic activities                      
Product revenues                 $ 45,295 $ 27,844 $ 21,763
Revenue from services and license revenues                 1,749 135 6,731
Less: Operating loss from noncontrolling interests                 (585)    
Operating (loss) income from continuing operations (1,064) (9,829) (10,245) (8,611) 10,381 (6,749) (5,347) (4,749) (37,269) (23,189) (11,136)
Depreciation and amortization                 10,160 3,830 2,207
Net loss from investments in investees                 (2,062) (1,589) (714)
Total revenues 16,261 11,795 10,211 8,777 5,794 6,807 8,428 6,950 47,044 27,979 28,494
Assets 289,830 [1]       229,489       289,830 [1] 229,489  
Goodwill 80,450 [1]       39,815       80,450 [1] 39,815  
Pharmaceutical [Member]
                     
Information regarding our geographic activities                      
Product revenues                 45,295 27,844 21,763
Revenue from services and license revenues                         
Operating (loss) income from continuing operations                 (6,797) (3,668) (3,257)
Depreciation and amortization                 6,367 2,804 2,092
Net loss from investments in investees                 (2,062) (1,589) (714)
Assets 142,299       90,409       142,299 90,409  
Goodwill 32,844       21,838       32,844 21,838  
Diagnostics [Member]
                     
Information regarding our geographic activities                      
Product revenues                         
Revenue from services and license revenues                 395    
Operating (loss) income from continuing operations                 (14,259) (3,984) (695)
Depreciation and amortization                 3,614 856  
Net loss from investments in investees                         
Assets 112,422       63,317       112,422 63,317  
Goodwill 47,606       17,977       47,606 17,977  
Corporate [Member]
                     
Information regarding our geographic activities                      
Product revenues                         
Revenue from services and license revenues                 1,354 135 6,731
Operating (loss) income from continuing operations                 (15,628) (15,537) (7,184)
Depreciation and amortization                 179 170 115
Net loss from investments in investees                         
Assets 35,109       75,759       35,109 75,759  
Goodwill                          
Discontinued operations [Member]
                     
Information regarding our geographic activities                      
Assets         4         4  
Goodwill                          
United States [Member]
                     
Information regarding our geographic activities                      
Total revenues                 1,749 135 6,731
Chile [Member]
                     
Information regarding our geographic activities                      
Total revenues                 26,514 21,466 17,977
Mexico [Member]
                     
Information regarding our geographic activities                      
Total revenues                 5,002 6,378 3,786
Israel [Member]
                     
Information regarding our geographic activities                      
Total revenues                 7,655    
Spain [Member]
                     
Information regarding our geographic activities                      
Total revenues                 $ 6,124    
[1] As of December 31, 2012, total assets include $5.6 million and total liabilities include $5.5 million related to SciGen (I.L.) Ltd, ("SciGen"), a consolidated variable interest entity. SciGen's consolidated assets are owned by SciGen and SciGen's consolidated liabilities are those as to which there is no recourse against us. Refer to Note 3.